GeneDx Holdings Corp. (NASDAQ:WGS) Director Richard C. Pfenniger, Jr. Acquires 5,000 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS – Get Rating) Director Richard C. Pfenniger, Jr. acquired 5,000 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was acquired at an average price of $5.90 per share, for a total transaction of $29,500.00. Following the completion of the purchase, the director now owns 5,918 shares of the company’s stock, valued at approximately $34,916.20. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

GeneDx Price Performance

NASDAQ WGS opened at $7.34 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.18 and a current ratio of 2.29. GeneDx Holdings Corp. has a one year low of $5.73 and a one year high of $81.84. The firm’s fifty day moving average is $8.81 and its two-hundred day moving average is $11.77.

GeneDx (NASDAQ:WGS – Get Rating) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($2.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($1.17). GeneDx had a negative return on equity of 115.70% and a negative net margin of 238.09%. The firm had revenue of $43.14 million for the quarter, compared to analyst estimates of $37.90 million. On average, analysts forecast that GeneDx Holdings Corp. will post -5.9 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Swiss National Bank lifted its holdings in shares of GeneDx by 7.9% in the first quarter. Swiss National Bank now owns 256,700 shares of the company’s stock valued at $788,000 after purchasing an additional 18,900 shares in the last quarter. Citigroup Inc. lifted its holdings in shares of GeneDx by 49.2% in the first quarter. Citigroup Inc. now owns 76,541 shares of the company’s stock valued at $235,000 after purchasing an additional 25,236 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of GeneDx by 5.8% in the first quarter. BlackRock Inc. now owns 2,456,595 shares of the company’s stock valued at $7,542,000 after purchasing an additional 133,789 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of GeneDx by 67.6% in the first quarter. Vanguard Group Inc. now owns 5,518,333 shares of the company’s stock valued at $16,941,000 after purchasing an additional 2,226,502 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of GeneDx by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 626,304 shares of the company’s stock valued at $1,923,000 after purchasing an additional 15,548 shares in the last quarter. 56.01% of the stock is currently owned by institutional investors and hedge funds.

GeneDx Company Profile

(Get Rating)

Sema4 Holdings Corp is a patient-centered health intelligence company. It is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 Holdings Corp, formerly known as CM Life Sciences, is based in STAMFORD, Conn.